search
Back to results

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer (NeoHTerMa)

Primary Purpose

HER2-negative Breast Cancer

Status
Recruiting
Phase
Phase 2
Locations
Hungary
Study Type
Interventional
Intervention
Oncotherm EHY-2030
Paclitaxel
Carboplatin
Cyclophosphamide/Doxorubicin
Breast cancer removal surgery
Sponsored by
Semmelweis University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HER2-negative Breast Cancer focused on measuring hyperthermia, modulated electro-hyperthermia, oncothermia, breast cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: At least 18 years of age Female patient Life expectancy ≥ 6 months De novo histological/cytological diagnosis of HER2-negative (triple-negative or ER/PR+) breast tumor involving one breast Diagnosis of breast tumor ≤ 40 days Locally advanced stage disease (stage II and III) requiring neoadjuvant treatment - according to the following criteria: Primary breast tumor ≥ 20 mm in size and/or Presence of axillary lymph node metastases Optimal surgical intervention without neoadjuvant chemotherapy is not feasible ECOG status: 0-2 Suitable for and designated by the investigator for neoadjuvant therapy with wTAX + (carboplatin) + AC chemotherapeutic agent Willingness to participate in the trial and signed the informed consent form for the protocol Exclusion Criteria: Patient is ≤ 18 years of age. Tumor of both breasts. Diagnosis of breast tumor > 40 days HER2 positive breast tumor Has already received some anticancer therapy Any previous cancer requiring anti-tumor treatment within 5 years prior to selection, except: in situ cervical or uterine cancer and non-melanoma skin cancer. Co-existing serious diseases: Presence of severe neuropathy requiring medical treatment, diabetic neuropathy. Clinically significant hematological, hepatic or renal dysfunction, as defined below: Neutrophil count < 1.5 G/L and platelet count < 100 G/L bilirubin > 1.5 times the upper limit of normal range (ULN), except for known Gilbert's disease AST and/or ALT > 2.5 times the upper limit of the normal range Serum creatinine > 1.5 times the upper limit of the normal range. Clinically significant cardiovascular disease in the medical history, unless the disease is adequately controlled. E.g. New York Heart Association (NYHA) Class II or worse congestive heart failure (moderate limitation of physical activity; well-being at rest but normal activity is associated with fatigue, rapid heart rate or dyspnoea). Uncontrolled hypertension with resting systolic ≥ 180 mmHg, resting diastolic ≥ 110 mmHg. Resting sinus tachycardia with a pulse ≥ 110/min. History of sympathetic or treatment-naive cardiac arrhythmia. Atrial fibrillation or flutter controlled with medication is not an exclusion for participation in the study. Major cardiovascular event (e.g. myocardial infarction, unstable angina, cerebral vascular accident (CVA), etc.) in the 6 months prior to randomisation. Active infection or severe underlying disease that renders the patient unfit for treatment according to the study protocol. A current diagnosis of chronic hepatitis, Hepatitis B surface antigen positive, Hepatitis C antibody positive and/or other clinically active liver disease requiring treatment. Known HIV infection. Untreated thyroid disease. Systemic autoimmune disease. Any psychiatric condition in the medical history that may result in the patient being unable to understand or comply with the requirements of the study, having reduced communication skills or being unable to give informed consent. Need for concomitant anti-tumor therapy in addition to wTAX + (carboplatin) + AC protocol Any active medical device implanted in the anatomical area, such as pacemakers. Known severe hypersensitivity to any of the chemotherapies used in the study. Pregnancy or breast-feeding (patients of childbearing potential must use effective contraception throughout the study and for 3 months after the end of treatment). The method of effective contraception is at the discretion of the investigator. History of drug or alcohol dependence within 6 months prior to screening. Unable to comply with the study plan for medical, psychological, family, geographical or other reasons. Institutionalisation by administrative or judicial decision.

Sites / Locations

  • Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

wTAX (+ carboplatin) +AC

wTAX (+ carboplatin) +AC + mEHT

Arm Description

wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x Breast cancer tumor removal surgery (if feasible)

wTAX + mWEHT wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x Breast cancer tumor removal surgery (if feasible)

Outcomes

Primary Outcome Measures

Residual size of the primary tumor, determined by imaging techniques (in percentage)
Using breast MR measurements, the the residual size of the primary tumor will be specified for all patients (in percentage). The comparison of these between the two study arms will serve as the primary outcome measure. Calculation: The tumor size after the 6-months treatment period (in mm) will be divided by the size measured prior treatment (in mm). The quotient will be given as a percentage and subtracted from 100.

Secondary Outcome Measures

Percentage of complete pathological response
Comparison of the percentage of complete pathological responses between the two groups
Treatment response patterns
Comparison of the pathological response categories (pCR : pPR : pNR) between the two groups
Comparison of surgical procedure ratios
It will be compared whether the ratio of two main breast surgery types (breast-conserving surgery vs. total mastectomy) differ between the two study arms.
Effect of treatment on white blood cell counts
White blood cell counts (in G/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Effect of treatment on red blood cell counts
Red blood cell counts (in T/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Effect of treatment on platelet counts
Platelet counts (in G/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Effect of treatment on hemoglobin levels
Hemoglobin level of patients (in g/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Effect of treatment on hematocrit levels
Hematocrit level of patients (in L/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Number of treatments where the planned power output of the Oncotherm EHY-2030 device could not be reached
For an optimal treatment, the Oncotherm EHY-2030 device must reach its maximum output for 30 minutes. The number of treatments where this optimal outpur could not be reached will be reported.
Longitudinal analysis of the EORTC QLQ-C30 questionnaire's total scores
The European Organisation for Research and Treatment of Cancer 30-item quality of life questionnaire for cancer patients (EORTC QLQ-C30) total scores will be calculated as per the official quidelines, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EORTC
Longitudinal analysis of the EORTC QLQ-BR23 questionnaire's total scores
The European Organisation for Research and Treatment of Cancer 23-item quality of life questionnaire for breast cancer patients (EORTC QLQ-BR23) total scores will be calculated as per the official quidelines, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EORTC
Longitudinal analysis of the EQ-5D-5L questionnaire scores
The questionnaire will be assessed as per official guidelines. EuroQol's 5-dimension health-related quality of life instrument (EQ-5D-5L) questionnaire scores' longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EuroQol.

Full Information

First Posted
March 3, 2023
Last Updated
May 25, 2023
Sponsor
Semmelweis University
search

1. Study Identification

Unique Protocol Identification Number
NCT05889390
Brief Title
Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer
Acronym
NeoHTerMa
Official Title
[A Prospective, Randomized Trial to Assess the Added Value of Concomitant Modulated Electro-hyperthermia in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy - an Investigator Initiated Study]
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 20, 2023 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
April 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Semmelweis University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
Detailed Description
This study is a pivotal, randomized (1:1), open-label, two-treatment group, single-centre trial of Oncotherm EHY-2030, a modulated electro-hyperthermia (mEHT) device. Female patients aged 18 years or older with locally advanced, unilaterally localized HER2-negative breast cancer requiring neoadjuvant treatment are eligible for the study. In the study, the wTAX (+ carboplatin) +AC neoadjuvant chemotherapy protocol will be administered according to the routine daily regimen, with or without mEHT three times a week during the wTAX (+ carboplatin) period. Carboplatin will be administered for patients with triple-negative breast cancer only. Primary objective: to compare whether the percentage of tumor size decrease determined by imaging techniques is different in the two treatment groups? Secondary and other objectives: Is complete pathological response (pCR) more common in the mEHT-treated group? Does the pattern of treatment response (pCR : pPR : pNR) differ between the two groups? Is the quality of life of patients different in the two study groups? Is there any treatment-related changes in the routine laboratory parameters such as blood count, liver enzymes, renal function? And do these differ in the two study arms? Safety and tolerability analysis of the device.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HER2-negative Breast Cancer
Keywords
hyperthermia, modulated electro-hyperthermia, oncothermia, breast cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
wTAX (+ carboplatin) +AC
Arm Type
Active Comparator
Arm Description
wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x Breast cancer tumor removal surgery (if feasible)
Arm Title
wTAX (+ carboplatin) +AC + mEHT
Arm Type
Experimental
Arm Description
wTAX + mWEHT wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x Breast cancer tumor removal surgery (if feasible)
Intervention Type
Device
Intervention Name(s)
Oncotherm EHY-2030
Intervention Description
Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
weekly paclitaxel for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
added to weekly paclitaxel if patient has triple-negative breast cancer
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide/Doxorubicin
Intervention Description
according to the AC protocol
Intervention Type
Procedure
Intervention Name(s)
Breast cancer removal surgery
Intervention Description
Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
Primary Outcome Measure Information:
Title
Residual size of the primary tumor, determined by imaging techniques (in percentage)
Description
Using breast MR measurements, the the residual size of the primary tumor will be specified for all patients (in percentage). The comparison of these between the two study arms will serve as the primary outcome measure. Calculation: The tumor size after the 6-months treatment period (in mm) will be divided by the size measured prior treatment (in mm). The quotient will be given as a percentage and subtracted from 100.
Time Frame
change from baseline at 6 months
Secondary Outcome Measure Information:
Title
Percentage of complete pathological response
Description
Comparison of the percentage of complete pathological responses between the two groups
Time Frame
9 months
Title
Treatment response patterns
Description
Comparison of the pathological response categories (pCR : pPR : pNR) between the two groups
Time Frame
9 months
Title
Comparison of surgical procedure ratios
Description
It will be compared whether the ratio of two main breast surgery types (breast-conserving surgery vs. total mastectomy) differ between the two study arms.
Time Frame
9 months
Title
Effect of treatment on white blood cell counts
Description
White blood cell counts (in G/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Time Frame
through study completion, an average of ~8 months
Title
Effect of treatment on red blood cell counts
Description
Red blood cell counts (in T/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Time Frame
through study completion, an average of ~8 months
Title
Effect of treatment on platelet counts
Description
Platelet counts (in G/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Time Frame
through study completion, an average of ~8 months
Title
Effect of treatment on hemoglobin levels
Description
Hemoglobin level of patients (in g/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Time Frame
through study completion, an average of ~8 months
Title
Effect of treatment on hematocrit levels
Description
Hematocrit level of patients (in L/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
Time Frame
through study completion, an average of ~8 months
Title
Number of treatments where the planned power output of the Oncotherm EHY-2030 device could not be reached
Description
For an optimal treatment, the Oncotherm EHY-2030 device must reach its maximum output for 30 minutes. The number of treatments where this optimal outpur could not be reached will be reported.
Time Frame
3 months
Title
Longitudinal analysis of the EORTC QLQ-C30 questionnaire's total scores
Description
The European Organisation for Research and Treatment of Cancer 30-item quality of life questionnaire for cancer patients (EORTC QLQ-C30) total scores will be calculated as per the official quidelines, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EORTC
Time Frame
through study completion, an average of ~8 months
Title
Longitudinal analysis of the EORTC QLQ-BR23 questionnaire's total scores
Description
The European Organisation for Research and Treatment of Cancer 23-item quality of life questionnaire for breast cancer patients (EORTC QLQ-BR23) total scores will be calculated as per the official quidelines, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EORTC
Time Frame
through study completion, an average of ~8 months
Title
Longitudinal analysis of the EQ-5D-5L questionnaire scores
Description
The questionnaire will be assessed as per official guidelines. EuroQol's 5-dimension health-related quality of life instrument (EQ-5D-5L) questionnaire scores' longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EuroQol.
Time Frame
through study completion, an average of ~8 months
Other Pre-specified Outcome Measures:
Title
Incidence of Treatment-Emergent Adverse Events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Description
All adverse events will be assessed and classified by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Using descriptive statistics, the number of occurrances will be listed for both study arms.
Time Frame
through study completion, an average of ~8 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least 18 years of age Female patient Life expectancy ≥ 6 months De novo histological/cytological diagnosis of HER2-negative (triple-negative or ER/PR+) breast tumor involving one breast Diagnosis of breast tumor ≤ 40 days Locally advanced stage disease (stage II and III) requiring neoadjuvant treatment - according to the following criteria: Primary breast tumor ≥ 20 mm in size and/or Presence of axillary lymph node metastases Optimal surgical intervention without neoadjuvant chemotherapy is not feasible ECOG status: 0-2 Suitable for and designated by the investigator for neoadjuvant therapy with wTAX + (carboplatin) + AC chemotherapeutic agent Willingness to participate in the trial and signed the informed consent form for the protocol Exclusion Criteria: Patient is ≤ 18 years of age. Tumor of both breasts. Diagnosis of breast tumor > 40 days HER2 positive breast tumor Has already received some anticancer therapy Any previous cancer requiring anti-tumor treatment within 5 years prior to selection, except: in situ cervical or uterine cancer and non-melanoma skin cancer. Co-existing serious diseases: Presence of severe neuropathy requiring medical treatment, diabetic neuropathy. Clinically significant hematological, hepatic or renal dysfunction, as defined below: Neutrophil count < 1.5 G/L and platelet count < 100 G/L bilirubin > 1.5 times the upper limit of normal range (ULN), except for known Gilbert's disease AST and/or ALT > 2.5 times the upper limit of the normal range Serum creatinine > 1.5 times the upper limit of the normal range. Clinically significant cardiovascular disease in the medical history, unless the disease is adequately controlled. E.g. New York Heart Association (NYHA) Class II or worse congestive heart failure (moderate limitation of physical activity; well-being at rest but normal activity is associated with fatigue, rapid heart rate or dyspnoea). Uncontrolled hypertension with resting systolic ≥ 180 mmHg, resting diastolic ≥ 110 mmHg. Resting sinus tachycardia with a pulse ≥ 110/min. History of sympathetic or treatment-naive cardiac arrhythmia. Atrial fibrillation or flutter controlled with medication is not an exclusion for participation in the study. Major cardiovascular event (e.g. myocardial infarction, unstable angina, cerebral vascular accident (CVA), etc.) in the 6 months prior to randomisation. Active infection or severe underlying disease that renders the patient unfit for treatment according to the study protocol. A current diagnosis of chronic hepatitis, Hepatitis B surface antigen positive, Hepatitis C antibody positive and/or other clinically active liver disease requiring treatment. Known HIV infection. Untreated thyroid disease. Systemic autoimmune disease. Any psychiatric condition in the medical history that may result in the patient being unable to understand or comply with the requirements of the study, having reduced communication skills or being unable to give informed consent. Need for concomitant anti-tumor therapy in addition to wTAX + (carboplatin) + AC protocol Any active medical device implanted in the anatomical area, such as pacemakers. Known severe hypersensitivity to any of the chemotherapies used in the study. Pregnancy or breast-feeding (patients of childbearing potential must use effective contraception throughout the study and for 3 months after the end of treatment). The method of effective contraception is at the discretion of the investigator. History of drug or alcohol dependence within 6 months prior to screening. Unable to comply with the study plan for medical, psychological, family, geographical or other reasons. Institutionalisation by administrative or judicial decision.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Attila M Szasz, M.D./Ph.D.
Phone
+3614591500
Ext
51618
Email
szasz.attila_marcell@med.semmelweis-univ.hu
First Name & Middle Initial & Last Name or Official Title & Degree
Zoltan Herold, Ph.D.
Phone
+3614591500
Email
herold.zoltan@med.semmelweis-univ.hu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Magdolna Dank, M.D./Ph.D.
Organizational Affiliation
Semmelweis University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University
City
Budapest
ZIP/Postal Code
1083
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Attila M Szasz, M.D./Ph.D.
Phone
+3614591500
Ext
51618
Email
szasz.attila_marcell@med.semmelweis-univ.hu
First Name & Middle Initial & Last Name & Degree
Zoltan Herold, Ph.D.
Phone
+3614591500
Email
herold.zoltan@med.semmelweis-univ.hu
First Name & Middle Initial & Last Name & Degree
Magdolna Dank, M.D./Ph.D.
First Name & Middle Initial & Last Name & Degree
Gyöngyvér Szentmártoni, M.D./Ph.D.
First Name & Middle Initial & Last Name & Degree
Magdolna Herold

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31737558
Citation
Szasz AM, Minnaar CA, Szentmartoni G, Szigeti GP, Dank M. Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist. Front Oncol. 2019 Nov 1;9:1012. doi: 10.3389/fonc.2019.01012. eCollection 2019.
Results Reference
background
PubMed Identifier
34616516
Citation
Herold Z, Szasz AM, Dank M. Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World J Gastrointest Oncol. 2021 Sep 15;13(9):1109-1120. doi: 10.4251/wjgo.v13.i9.1109.
Results Reference
background
PubMed Identifier
34842668
Citation
Petenyi FG, Garay T, Muhl D, Izso B, Karaszi A, Borbenyi E, Herold M, Herold Z, Szasz AM, Dank M. Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients-A Single-Center Case-Control Study. Diseases. 2021 Nov 3;9(4):81. doi: 10.3390/diseases9040081.
Results Reference
background
PubMed Identifier
36765840
Citation
Szasz AM, Arrojo Alvarez EE, Fiorentini G, Herold M, Herold Z, Sarti D, Dank M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas. Cancers (Basel). 2023 Jan 31;15(3):880. doi: 10.3390/cancers15030880.
Results Reference
background

Learn more about this trial

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

We'll reach out to this number within 24 hrs